Foreign

Roundup: U.S. health organization starts clinical trial of hydroxychloroquine, azithromycin to treat COVID-19

Published

on

A clinical trial has begun in the United States to evaluate whether anti-malaria drug hydroxychloroquine, given together with antibiotic azithromycin, can prevent COVID-19 hospitalization and death, according to a release published by the U.S. National Institutes of Health (NIH) on Thursday.

Hydroxychloroquine is approved by U.S. Food and Drug Administration (FDA) to prevent and treat malaria, as well as to treat the autoimmune diseases rheumatoid arthritis and lupus. And azithromycin is FDA-approved antibiotic.

The trial will enroll approximately 2,000 adults across the United States, who are infected with SARS-CoV-2, the novel coronavirus that causes COVID-19, and exhibiting symptoms of fever, cough or shortness of breath, according to the release.

The investigators anticipate that many participants will be 60 years of age or over, or have a comorbidity associated with developing serious complications from COVID-19, such as cardiovascular disease or diabetes, NIH said.

Participants will be randomly assigned to receive short-term treatment at home with either hydroxychloroquine and azithromycin or matching placebos, it said.

Those assigned to the experimental treatment group will take 400 milligrams of hydroxychloroquine twice on the first day, and 200 mg twice daily for an additional six days. They will also take 500 mg of azithromycin on the first day, and 250 mg daily for an additional four days.

The control group will receive equivalent numbers of placebo pills, and neither the participants nor the study team will know who received experimental treatment or placebo until the end of the trial, according to the NIH.

Participants will record their symptoms, adherence to treatment, and major events such as hospitalizations in a diary for 20 days.

The first participant has enrolled on Thursday in San Diego, California. And Teva Pharmaceuticals is donating medications for the study, according to the NIH.

Currently, there are no specific therapeutics approved by the FDA to treat people with COVID-19.

Many clinical trials are planned or underway to evaluate the safety and effectiveness of hydroxychloroquine for treatment of adults hospitalized with COVID-19, and some preliminary reports have suggested that hydroxychloroquine, alone or in combination with azithromycin, may benefit people with COVID-19, according to the NIH.

The NIH said that the main objective of the study is to determine whether hydroxychloroquine and azithromycin can prevent hospitalization and death due to COVID-19. Additionally, investigators will evaluate the safety and tolerability of the experimental treatment for people with SARS-CoV-2 infection.

The FDA issued an Emergency Use Authorization on March 28 to allow hydroxychloroquine and medical-grade chloroquine to be distributed from the Strategic National Stockpile and prescribed by doctors, to hospitalized adolescents and adults with COVID-19, when a clinical trial is not available or feasible.

(XINHUA)

Short Link: https://wp.me/pcj2iU-3d5L

NNN

NNN: :is a Nigerian online news portal that publishes breaking news in Nigeria, and across the world. Our journalists are honest, fair, accurate, thorough and courageous in gathering, reporting and interpreting news in the best interest of the public, because truth is the cornerstone of journalism and they strive diligently to ascertain the truth in every news report. Contact: editor @ nnn.ng

Ghana denies Akufo-Addo’s alleged conviction against Nigeria Tragic death of Bello Africa’s best para-badminton player – Kwara gov. Presidency condemns smear campaign against Minister of Communication Pantami Ramadan: Governor Lalong and Onaiyekan call for peace and religious tolerance Zamfara’s killing of innocent people by bandits is unacceptable – Buhari FG reaffirms its commitment to finance the schools of the unit ACCI entrusts the private sector with piloting the agro-industrial zones COVID-19: 16.6 million African children miss doses of measles vaccine – WHO FG reiterates its commitment to the industrial property legislature Police debunk 18 passenger kidnapping in Oyo state Minister calls for private sector participation in nuclear technology Community projects funded by the World Bank, best FG- Kebbi Govt initiative IOM reaffirms its commitment to combat human trafficking The Institute of Sales and Marketing welcomes 30 members Lagos to generate $ 10 billion in agricultural investments by 2025 – Sanwo-Olu Houseboy machete madam to death in Ondo Measles outbreak looms in Africa as vaccination stalls – WHO FG travels to verify bragging, extortion by passport officers Banditry: Buhari meets 7 Governments of N / West, N / Central Restlessness: NEC affirms Nigeria’s unity The FG declares its readiness to support women farmers in MSMEs NEC provides update on railway infrastructure development 50 first-class graduates get TESCOM jobs in Kwara Group to plant 10,000 trees in FCT Death of Deby: AU must find a solution to Chad’s problems – FG FCTA identifies SMEs as panacea for economic growth Senate pledges to fight rot in education sector Coronavirus – Malawi: COVID-19 update (April 21, 2021) Forex Restriction: Nigeria Spends $ 6.1 Billion Per Year On Importing Wheat – WFAN Coronavirus – Eritrea: Ministry of Health announcement (April 21, 2021) ICT: the Minister seeks the participation of women to promote gender equality Coronavirus – Nigeria: COVID-19 update (April 21, 2021) OML 143: NNPC and SEEPCO sign a gas development agreement UNFPA donates PPE to 33 health facilities in Ogun to fight COVID-19 Kano / Jigawa Customs Command generates N 7.6 billion in Q1 2021 Coronavirus – Ethiopia: COVID-19 update (April 21, 2021) Coronavirus – Zambia: COVID-19 update (April 21, 2021) Mango growers plan 6 juice processing plants in 2021 Coronavirus – Gambia: COVID-19 update (April 21, 2021) Revocation: DPR inaugurates a committee for the official handover of Addax assets Police deploy 1,000 people to control traffic thefts in Lagos How we have spent the COVID-19 funds so far – FG Coronavirus – South Africa: COVID-19 update (April 21, 2021) Buhari greets 85-year-old Emir of Gwandu Coronavirus – Namibia: COVID-19 update (April 21, 2021) The Impact of Transfer Pricing: The Senegalese Branch and the Foreign Head Office (By Centurion Tax and Investment Desk) 19 African First Ladies to attend the Merck Foundation Annual Online Conference on April 27, 2021 Coronavirus – Niger: COVID-19 update (April 21, 2021) Coronavirus – Kenya: COVID-19 update (April 21, 2021) JUSUN and PASAN refuse to end the strike, insist on the demands